Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900945 | 0.97 | POLB (0.58) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL2245806 | 0.93 | RAB9A (0.65) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL15943127 | 0.84 | RAB9A (0.55) | RAB9ACA12CA1CA2CA7 | |
| Cyclohexane SCHEMBL2917907 | 0.82 | CA1 (0.73) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL11901124 | 0.81 | CA12 (0.53) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL25233963 | 0.80 | RAB9A (0.89) | RAB9APOLBCYP1A2LMNAALDH1A1 | |
| SCHEMBL1363417 | 0.80 | ALDH1A1 (0.59) | RAB9APOLBALDH1A1HTTHPGD | |
| SCHEMBL87450 | 0.80 | CA1 (0.83) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL11901153 | 0.80 | CA12 (0.51) | RAB9ACA12CA1CA2CA7 | |
| SCHEMBL8119800 | 0.78 | KMT2A (0.68) | RAB9APOLBCYP1A2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9452999-B2 | Glucagon receptor modulators | PFIZER INC. (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2673260-B1 | GLUCAGON RECEPTOR MODULATOR | PFIZER (US) | 2016-08-17 | — | — | EP | disclosed |
| CN-103370306-B | Glucagon Receptor Modulators | PFIZER INC. (US) | 2015-12-02 | — | — | CN | disclosed |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | PFIZER INC. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20070043014-A1 | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | MERCK & CO., INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060252741-A1 | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | MERCK & CO., INC. | 2006-11-09 | — | — | US | disclosed |
| CN-1859908-A | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists | MERCK & CO INC (US) | 2006-11-08 | — | — | CN | disclosed |
| EP-1670463-A2 | 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-06-21 | — | — | EP | disclosed |
| CN-1788008-A | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists | MERCK & CO INC (US) | 2006-06-14 | — | — | CN | disclosed |
| WO-2006044602-A9 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO INC (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006044602-A2 | DIPHENYL SUBSTITUTED ALKANES AS FLAP INHIIBITORS | MERCK & CO., INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1625123-A2 | 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| WO-2005032465-A2 | 3,5-ARYL, HETEROARYL OR CYCLOALKYL SUBSTITUTED-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004103279-A2 | 3-(2-AMINO-1-AZACYCLYL)-5-ARYL-1,2,4-OXADIAZOLES AS S1P RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043014-A1 | 3,5-Aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists | S1PR3, S1PR1, S1PR5 | RAB9A 3645/4885CA12 4871/4885CA1 4857/4885 |
| US-20150266859-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | RAB9A 1825/4885CA12 2808/4885CA1 3307/4885 |
| US-20060252741-A1 | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists | S1PR1, S1PR3, S1PR5 | RAB9A 2918/4885CA12 4853/4885CA1 4812/4885 |
| US-20160362392-A1 | GLUCAGON RECEPTOR MODULATORS | GLP1R, GCGR, GPR119 | RAB9A 1825/4885CA12 2808/4885CA1 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.